Correlation between TGF-β1 gene 29 T > C single nucleotide polymorphism and clinicopathological characteristics of osteosarcoma

Tumor Biology

Volumn 36, Issue 7, 2015, Pages 5149-5156

  Wu, Yang ^a   Zhao, Jinmin ^a   He, Maolin ^b  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Clinicopathological characteristics; Osteosarcoma; Single nucleotide polymorphism; TGF 1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE LOCUS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; TGF BETA1 GENE; AGED; CANCER STAGING; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OSTEOSARCOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84938207262     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3168-x     Document Type: Article

References (26)

1. Gill J, Ahluwalia MK, Geller D, Gorlick R. New targets and approaches in osteosarcoma. Pharmacol Ther. 2013;137(1):89–99.
2. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.
3. Bielack SS, Kempf-Bielack B, Branscheid D, Carrle D, Friedel G, Helmke K, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol. 2009;27(4):557–65.
4. Gorlick R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res. 2009;152:467–78.
5. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, et al. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature. 1985;316(6030):701–5.
6. Mantel PY, Schmidt-Weber CB. Transforming growth factor-beta: recent advances on its role in immune tolerance. Methods Mol Biol. 2011;677:303–38.
7. Kloen P, Gebhardt MC, Perez-Atayde A, Rosenberg AE, Springfield DS, Gold LI, et al. Expression of transforming growth factor-beta (TGF-beta) isoforms in osteosarcomas: TGF-beta3 is related to disease progression. Cancer. 1997;80(12):2230–9.
8. Franchi A, Arganini L, Baroni G, Calzolari A, Capanna R, Campanacci D, et al. Expression of transforming growth factor beta isoforms in osteosarcoma variants: association of TGF beta 1 with high-grade osteosarcomas. J Pathol. 1998;185(3):284–9.
9. Amirghofran Z, Jalali SA, Ghaderi A, Hosseini SV. Genetic polymorphism in the transforming growth factor beta1 gene (-509 C/T and -800 G/A) and colorectal cancer. Cancer Genet Cytogenet. 2009;190(1):21–5.
10. Minamiya Y, Miura M, Hinai Y, Saito H, Ito M, Ono T, et al. Transforming growth factor-beta1 29 T > C genetic polymorphism is associated with lymph node metastasis in patients with adenocarcinoma of the lung. Tumour Biol. 2010;31(5):437–41.
11. Wang Y, Chu X, Meng X, Zou F. Association of TGF-beta1–509C/T polymorphisms with breast cancer risk: evidence from an updated meta-analysis. Tumour Biol. 2014;35(2):935–42.
12. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet. 1999;8(1):93–7.
13. Silverman ES, Palmer LJ, Subramaniam V, Hallock A, Mathew S, Vallone J, et al. Transforming growth factor-beta1 promoter polymorphism C-509 T is associated with asthma. Am J Respir Crit Care Med. 2004;169(2):214–9.
14. Yamada Y, Miyauchi A, Takagi Y, Tanaka M, Mizuno M, Harada A. Association of the C-509-- > T polymorphism, alone of in combination with the T869-- > C polymorphism, of the transforming growth factor-beta1 gene with bone mineral density and genetic susceptibility to osteoporosis in Japanese women. J Mol Med (Berl). 2001;79(2-3):149–56.
15. Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF. Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis. Bone. 2003;32(3):297–310.
16. Xu S, Yang S, Sun G, Huang W. Zhang Y. DNA Cell Biol: Transforming growth factor-beta polymorphisms and serum level in the development of osteosarcoma; 2014.
17. Schedlich LJ, Yenson VM, Baxter RC. TGF-beta-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells. Mol Cell Endocrinol. 2013;377(1–2):56–64.
18. Langdahl BL, Knudsen JY, Jensen HK, Gregersen N, Eriksen EF. A sequence variation: 713-8delC in the transforming growth factor-beta 1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone. 1997;20(3):289–94.
19. Langdahl BL, Uitterlinden AG, Ralston SH, Trikalinos TA, Balcells S, Brandi ML, et al. Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: the GENOMOS study. Bone. 2008;42(5):969–81.
20. Tang RG, Huang YZ, Yao LM, Xiao J, Lu C, Yu Q. Polymorphisms of transforming growth factor beta 1 (RS#1800468 and RS#1800471) and esophageal squamous cell carcinoma among Zhuangese population, China. Gene. 2013;512(1):1–5.
21. Ewart-Toland A, Chan JM, Yuan J, Balmain A, Ma J. A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(5):759–64.
22. Shu XO, Gao YT, Cai Q, Pierce L, Cai H, Ruan ZX, et al. Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res. 2004;64(3):836–9.
23. Saha A, Gupta V, Bairwa NK, Malhotra D, Bamezai R. Transforming growth factor-beta1 genotype in sporadic breast cancer patients from India: status of enhancer, promoter, 5′-untranslated-region and exon-1 polymorphisms. Eur J Immunogenet. 2004;31(1):37–42.
24. Rajkumar T, Samson M, Rama R, Sridevi V, Mahji U, Swaminathan R, et al. TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. Breast Cancer Res Treat. 2008;112(1):81–7.
25. Joshi NN, Kale MD, Hake SS, Kannan S. Transforming growth factor beta signaling pathway associated gene polymorphisms may explain lower breast cancer risk in western Indian women. PLoS One. 2011;6(8):e21866.
26. Zhang HY, Wang ZQ, Li YY, Wang F, Zeng QR, Gao Y, et al. Transforming growth factor-beta1-induced epithelial-mesenchymal transition in human esophageal squamous cell carcinoma via the PTEN/PI3K signaling pathway. Oncol Rep. 2014.